NCT03684694

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE1, PHASE2

Sponsor: ADC Therapeutics S.A.

Condition: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma

Signal summary

Status signal: Registry Stop Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Administrative decision